TRACON Pharmaceuticals, Inc. (TCON): Price and Financial Metrics


TRACON Pharmaceuticals, Inc. (TCON): $1.67

0.03 (+1.83%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add TCON to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

TCON POWR Grades


  • Sentiment is the dimension where TCON ranks best; there it ranks ahead of 63.29% of US stocks.
  • The strongest trend for TCON is in Growth, which has been heading down over the past 173 days.
  • TCON's current lowest rank is in the Momentum metric (where it is better than 4.62% of US stocks).

TCON Stock Summary

  • The capital turnover (annual revenue relative to shareholder's equity) for TCON is 0.03 -- better than merely 8.48% of US stocks.
  • With a price/sales ratio of 155.91, Tracon Pharmaceuticals Inc has a higher such ratio than 98.2% of stocks in our set.
  • With a year-over-year growth in debt of -66.15%, Tracon Pharmaceuticals Inc's debt growth rate surpasses only 4.51% of about US stocks.
  • If you're looking for stocks that are quantitatively similar to Tracon Pharmaceuticals Inc, a group of peers worth examining would be SEAC, RIGL, MDRX, ALLT, and ARAY.
  • Visit TCON's SEC page to see the company's official filings. To visit the company's web site, go to www.traconpharma.com.

TCON Valuation Summary

  • TCON's EV/EBIT ratio is -2.3; this is 107.85% lower than that of the median Healthcare stock.
  • Over the past 80 months, TCON's price/earnings ratio has gone up 12.5.
  • Over the past 80 months, TCON's price/earnings ratio has gone up 12.5.

Below are key valuation metrics over time for TCON.

Stock Date P/S P/B P/E EV/EBIT
TCON 2021-08-31 210.1 6.1 -3.3 -2.3
TCON 2021-08-30 209.5 6.1 -3.3 -2.3
TCON 2021-08-27 213.9 6.2 -3.3 -2.3
TCON 2021-08-26 213.3 6.2 -3.3 -2.3
TCON 2021-08-25 224.6 6.5 -3.5 -2.5
TCON 2021-08-24 221.4 6.4 -3.4 -2.5

TCON Growth Metrics

    Its 5 year net cashflow from operations growth rate is now at -4.09%.
  • Its 4 year price growth rate is now at -96.38%.
  • Its 3 year price growth rate is now at -89.01%.
Over the past 52 months, TCON's revenue has gone down $9,026,000.

The table below shows TCON's growth in key financial areas (numbers in millions of US dollars).

Date Revenue Operating Cash Flow Net Income to Common Stock
2021-12-31 0.346 -22.571 -28.667
2021-09-30 0.346 -21.083 -25.266
2021-06-30 0.346 -16.928 -22.306
2021-03-31 0 -16.609 -17.818
2020-12-31 0 -17.042 -16.775
2020-09-30 0 -17.659 -16.4

TCON's Quality Factors

The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.
  • TCON has a Quality Grade of C, ranking ahead of 39.83% of graded US stocks.
  • TCON's asset turnover comes in at 0.011 -- ranking 386th of 681 Pharmaceutical Products stocks.
  • ATXS, PTCT, and ZIOP are the stocks whose asset turnover ratios are most correlated with TCON.

The table below shows TCON's key quality metrics over time.

Period Asset Turnover Gross Margin ROIC
2021-06-30 0.011 1 5.011
2021-03-31 0.000 NA 6.881
2020-12-31 0.000 NA 5.950
2020-09-30 0.000 NA 4.354
2020-06-30 0.000 NA 4.418
2020-03-31 0.000 NA 4.304

TCON Price Target

For more insight on analysts targets of TCON, see our TCON price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.

Average Price Target $14.75 Average Broker Recommendation 1.43 (Moderate Buy)

TCON Stock Price Chart Interactive Chart >

Price chart for TCON

TCON Price/Volume Stats

Current price $1.67 52-week high $7.42
Prev. close $1.64 52-week low $1.61
Day low $1.61 Volume 83,000
Day high $1.71 Avg. volume 115,355
50-day MA $2.40 Dividend yield N/A
200-day MA $2.97 Market Cap 33.18M

TRACON Pharmaceuticals, Inc. (TCON) Company Bio


Tracon Pharmaceuticals develops targeted therapies for cancer, wet age-related macular degeneration and fibrotic diseases. The company was founded in 2004 and is based in San Diego, California.


TCON Latest News Stream


Event/Time News Detail
Loading, please wait...

TCON Latest Social Stream


Loading social stream, please wait...

View Full TCON Social Stream

Latest TCON News From Around the Web

Below are the latest news stories about Tracon Pharmaceuticals Inc that investors may wish to consider to help them evaluate TCON as an investment opportunity.

Analysts Offer Insights on Healthcare Companies: Seagen (SGEN) and TRACON Pharmaceuticals (TCON)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Seagen (SGEN – Research Report) and TRACON Pharmaceuticals (TCON – Research Report) with bullish sentiments. Seagen (SGEN) H.C. Wainwright analyst Andrew Fein maintained a Buy rating on Seagen today and set a price target of $200.00. The company's shares closed last Thursday at $134.85. According to TipRanks.

Christine Brown on TipRanks | February 3, 2022

TRACON Pharmaceuticals Announces Initiation of Randomized Phase 2 Trial of TRC102 in Lung Cancer Sponsored by the National Cancer Institute

SAN DIEGO, Feb. 02, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics today announced that the National Cancer Institute (NCI) has initiated a randomized Phase 2 trial of TRC102 in combination with chemoradiation in patients with stage III non-squamous non-small cell lung cancer (NCT05198830: https://clinicaltrials.gov/ct2/show/NCT05198830?term=TRC102&dr

Yahoo | February 2, 2022

TRACON Pharmaceuticals to Present at the H.C. Wainwright BIOCONNECT Virtual Conference

SAN DIEGO, Jan. 05, 2022 (GLOBE NEWSWIRE) -- TRACON Pharmaceuticals (NASDAQ: TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted cancer therapeutics and utilizing a cost efficient, CRO-independent product development platform to partner with ex-U.S. companies to develop and commercialize innovative products in the U.S., today announced that Charles Theuer, M.D., Ph.D., President and Chief Executive Officer, will present a corporate

Yahoo | January 5, 2022

3 Top Penny Stocks for 2022

Penny stocks are defined as stocks that trade at less than $5 a share. While penny stocks continue to be a risky bet, they are still popular among investors. These stocks may be volatile, but with due diligence, some hidden treasures may be found. Such penny stocks trading at low share prices can translate to huge gains for retail investors in terms of percentage returns. Using the TipRanks penny stock screener, let us find some of the top penny stocks. Bolt Biotherapeutics (NASDAQ: BOLT) The first one on this list is Bolt Biotherapeutics, a clinical-stage biotechnology company founded in 2015 by Dr. Edgar G. Engleman of Stanford University.

Shrilekha Pethe on TipRanks | December 29, 2021

Analysts’ Top Healthcare Picks: BridgeBio Pharma (BBIO), TRACON Pharmaceuticals (TCON)

There's a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on BridgeBio Pharma (BBIO – Research Report) and TRACON Pharmaceuticals (TCON – Research Report) with bullish sentiments. BridgeBio Pharma (BBIO) In a report released yesterday, Thomas Shrader from BTIG maintained a Buy rating on BridgeBio Pharma, with a price target of $32.00. The company's shares closed last Monday at $11.38. According to TipRanks.

Austin Angelo on TipRanks | December 28, 2021

Read More 'TCON' Stories Here

TCON Price Returns

1-mo N/A
3-mo -35.77%
6-mo -47.32%
1-year -72.89%
3-year -78.99%
5-year -94.91%
YTD -39.71%
2021 -76.32%
2020 400.00%
2019 -62.86%
2018 -81.19%
2017 -31.63%

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5171 seconds.